Cannabichromene Showed Antidepressant Effects Comparable to Imipramine in Stressed Mice | Research

The takeaway

The non-psychoactive cannabinoid cannabichromene (CBC) reduced depression-like behavior in chronically stressed mice at 20 mg/kg, performing comparably to the antidepressant imipramine, likely through CB2 receptor interaction.

Psychopharmacology researchers, psychiatrists interested in novel antidepressants, and cannabinoid scientists.

What the researchers found

CBC at 20 mg/kg significantly reduced immobility in stressed mice (comparable to imipramine 15 mg/kg) without affecting locomotor activity. Both CBC and imipramine reduced elevated plasma nitrite and corticosterone and inhibited brain monoamine oxidase-A. In silico modeling showed CBC had stronger CB2 receptor binding (docking score: -9.4) than CBD (-8.8) or THC (-9.1).

Why it matters

CBC is one of the least-studied major cannabinoids. Finding antidepressant activity comparable to a standard antidepressant, mediated through CB2 receptors rather than the psychoactive CB1 pathway, opens a potential avenue for non-psychoactive cannabinoid-based treatments for depression.

The numbers in context

CBC 20 mg/kg: significant immobility reduction (comparable to imipramine 15 mg/kg). CB2 docking scores: CBC -9.4, THC -9.1, CBD -8.8. CBC reduced plasma nitrite and corticosterone. CBC inhibited brain MAO-A activity. CBC reversed stress-induced catalase suppression. No locomotor effects.

How the study worked

Male Swiss albino mice underwent 3 weeks of chronic unpredictable mild stress. CBC (10 and 20 mg/kg) and imipramine (15 mg/kg) administered for 21 days. Behavioral testing (forced swim, locomotor activity), plasma biochemistry (nitrite, corticosterone), and brain enzyme assays (MAO-A, catalase) performed. In silico target prediction and molecular docking complemented in vivo findings.

What this study cannot tell us

Single mouse strain (Swiss albino males only). CUMS model does not fully replicate human depression. In silico CB2 binding prediction needs experimental confirmation. 21-day treatment may not reflect chronic use effects. Dose-response showed efficacy only at 20 mg/kg, not 10 mg/kg.

How to read the evidence

Combined in silico and in vivo approach with appropriate positive control, but single species, single sex, and single stress model limit confidence.

When this study was published

Published 2025.

The bigger picture

Depression treatment needs new approaches: current antidepressants fail 30-40% of patients. CBC offers a non-psychoactive cannabinoid alternative working through a novel mechanism (CB2 receptors and MAO-A inhibition). However, this is a single mouse study and must be validated in multiple models before clinical translation.

Questions still open

Whether CBC's antidepressant effects hold up in other animal models and in females
Whether CBC could be combined with existing antidepressants for enhanced efficacy

Common questions

What is cannabichromene?

CBC is the third most abundant cannabinoid in cannabis after THC and CBD. It is non-psychoactive and has received much less research attention than either THC or CBD. This study suggests it may have distinct therapeutic properties through CB2 receptor interaction.

How does CBC compare to CBD for depression?

This study's molecular docking showed CBC binds more strongly to CB2 receptors than CBD. The in vivo antidepressant effects were tested for CBC but not directly compared to CBD in the same experiment, so a head-to-head comparison is still needed.

Read the original research

Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.

Naunyn-Schmiedeberg's archives of pharmacology, 398(11), 15611-15630

View on PubMed ↗Publisher’s paper ↗

Citation

Sharma, Abhishek; Singh, Rahul; Virmani, Tarun; Chouhan, Neeraj Kumar; Kapoor, Garima; Kumar, Girish; Bhutani, Rubina; Rana, Neha; Sharma, Shivkant. (2025). Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.. Naunyn-Schmiedeberg's archives of pharmacology, 398(11), 15611-15630. https://doi.org/10.1007/s00210-025-04236-2